Menu
Log in

EVENT DETAILS

Cannabis and Cannabinoids in 2023 Kevin Hill, MD Approved for 3 CEs

  • September 15, 2023
  • 9:00 AM - 12:00 PM
  • Danversport Yacht Club 101 Elliot Street, Danvers, MA & Zoom

Registration


Registration is closed

Cannabis policies are constantly changing.  Massachusetts has had medical and recreational laws in place for many years now. As a result, many of our patients are either interested in using cannabis or cannabinoids or are already doing so.  Clinicians need to know the latest cannabis science in order to talk about cannabis with their patients in a sensible, evidence-based manner. 

Many people use cannabis or other cannabinoids like CBD to treat a wide array of medical problems.  The evidence supports the use of cannabis or cannabinoids for some of these conditions, but for many, it does not.  In this seminar, Dr. Hill will review the evidence for both the risks and the benefits of cannabis and cannabinoids like CBD so that healthcare professionals can help patients make more informed choices about using these complex substances.  

For a subset of individuals, their cannabis use escalates into a problem in key spheres of their lives like work, school, or relationships.  Many of these people don’t seek treatment unfortunately.  For those that do, however, we will discuss the treatment of individuals with cannabis use disorder.

Dr. Kevin Hill is Director of Addiction Psychiatry at Beth Israel Deaconess Medical Center (BIDMC) an Associate Professor of Psychiatry at Harvard Medical School.  He earned a Master’s in Health Science at the Robert Wood Johnson Clinical Scholars Program at the Yale  School of Medicine.   He most commonly treats patients who have problems with alcohol, cannabis, or opioids.  The author of Marijuana: The Unbiased Truth about the World’s Most Popular Weed, Dr. Hill’s research interests include the development of medications to treat cannabis use disorder as well as cannabis policy, and he has published widely on these topics in such journals as JAMA, JAMA Internal Medicine, and Lancet Psychiatry.  In 2018, he was awarded a grant to summarize the research on the therapeutic use of cannabis and he presented his findings to the World Health Organization’s Expert Committee on Drug Dependence in Geneva, Switzerland in June 2018.  He serves on the editorial boards of Lancet Psychiatry, Cannabis and Cannabinoid Research, and American Journal on Addictions.

Learning Objectives: 

Describe the epidemiology of cannabis use as policies have changed. 

 Explain acute and chronic risks of cannabis use. 

Discuss current state of the evidence for the therapeutic use of cannabis.

Identify challenges associated with the increasing popularity of cannabidiol.

Agenda:

9:00-9:50  Changing Cannabis Policy in 2023 and Review of Risks

10-10:50  The Evidence for Therapeutic Use

11-11:30  Treatment of Cannabis Use Disorder

11:30-12  Wrap-Up and Final Q and A.

Bibliography:

Hill, K.P., Gold, M.S., Nemeroff, C.B., McDonald, W., Grzenda, A., Widge, A.S., Rodriguez, C., Kraguljac, N.V., Krystal, J.H., Carpenter, L.L. Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. Am J Psychiatry. 2021 Dec 8:appiajp202121030320. doi: 10.1176/appi.ajp.2021.21030320. Online ahead of print.

Hill, K.P. Marijuana: The Unbiased Truth About the World’s Most Popular Weed. Hazelden Publishing, March, 2015.-

Hill, K.P. Clinical Crossroads: Medical Marijuana for the Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Systematic Review. JAMA, 2015 Jun 23-30;313(24):2474-83.

Burnett, G.M., Gorelick, D.A. Hill, K.P. Policy ahead of the science: Medical cannabis laws versus scientific evidence. Psychiatr Clin N Am. 2022. https://doi.org/10/1016/j.psc.2022.05.002.

This presentation is suitable for a beginning level in the subject matter.

There is no known commercial support nor conflict of interest for this program.

It is the participant's responsibility to check with their individual state boards to verify CE requirements for their state. 


The CE Company is approved by the American Psychological Association to sponsor continuing education for psychologists. The CE Company maintains responsibility for this program and its contents.

Participants should always check with their state's licensure board regarding the acceptance of APA CE credits. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine program eligibility.

Continuing education credit is awarded by the CE Company for the following disciplines:

Social Workers:

The CE Company is entitled to award continuing education credit for Social Workers. Please visit The CE Company to see all states that are covered for Social Workers. The CE Company maintains responsibility for this program and its content. Social Workers completing this program will receive 3.0 clinical hours of clinical continuing education credit.

Licensed Mental Health Counselors/Licensed Clinical Professional Counselors:

The CE Company is entitled to award continuing education credit for Licensed Professional Counselors/Licensed Mental Health Counselors. Please visit The CE Company to see all states that are covered for LPCs/LMHCs. The CE Company maintains responsibility for this program and its content. LPCs/LMHCs completing this program will receive 3.0 hours of continuing education credit.

Psychologists:

The CE Company is approved by the American Psychological Association to sponsor continuing education for Psychologists. The CE Company maintains responsibility for this program and its content. Psychologists receive 3.0 hours of continuing education credit upon completing this program. Please visit The CE Company for further information.

Nurses:

As an American Psychological Association approved provider, the CE Company programs are accepted by the American Nurses Credentialing Center (ANCC). Nurses completing this program will receive 3.0 hours of continuing education credit. Please visit The CE Company for further information.

Licensed Marriage & Family Therapists:

The CE Company is entitled to award continuing education credit for Licensed Marriage & Family Therapists. Please visit The CE Company to see all states that are covered for LMFTs. CES maintains responsibility for this program and its content. LMFTs completing this program will receive 3.0 hours of continuing education credit.

Cancellation Policy:

Cancellation of your registration with full refund can be done up to 7 days before the event. Simply send an email requesting to cancel to ppcsalem@gmail.com.

Accommodations for the Differently Abled:

The CE Company's training facilities are handicap accessible. Individuals needing special accommodations, please contact the Private Practice Colloquium ppcsalem@gmail.com.

Grievance Policy:

The Private Practice Colloquium, Inc. (PPC) and The CE Company seek to ensure equitable treatment of every person and to make every attempt to resolve grievances in a fair manner. Please submit a written grievance to PPC, 564 Loring Avenue, Salem, MA 01970 or to The CE Company. Grievances will initially be directed to the training instructor. Grievances would receive, to the best of our ability, corrective action in order to prevent further problems. If you have questions or concerns, contact PPC at  ppcsalem@gmail.com or The CE Company at support@thececompany.com.

CONTACT

Private Practice Colloquium, Inc.
49 Elmwood Street 

PO  Box 281

Swampscott, MA 01907

Email: ppcsalem@gmail.com